Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darusentan in resistant hypertension
ACTRN12606000446561Phase 3Not yet recruiting
- Sponsor
- Myogen
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darusentan in resistant hypertension (RH) (3 arms), sponsored by Myogen. Primary endpoint: Trough sitting systolic and diastolic blood pressure by sphygmomanometry. Planned start Jan 2007; status: not yet recruiting.
02
Drugs
darusentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on ACTRN12606000446561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000446561.